Pathos AI vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
Pathos AI logo

Pathos AI

ChallengerHealthcare & Life Sciences

AI Oncology

Clinical-stage AI company raised $365M Series D at $1.6B for world's largest multimodal oncology AI; Novo Nordisk partnership; $467M total;

AI VisibilityBeta
Overall Score
C52
Category Rank
#289 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
48
Perplexity
54
Gemini
50

About

Pathos AI is a clinical-stage AI company building the world's largest multimodal oncology AI platform, combining pathology imaging, genomics, clinical records, and treatment outcome data to power precision cancer care. Founded by oncologists, pathologists, and AI researchers, Pathos has assembled a dataset at a scale that gives its models a meaningful edge: by ingesting vast quantities of multimodal cancer data, its platform can predict treatment responses, identify biomarkers, and guide therapy selection with a level of accuracy that single-modality systems cannot match.\n\nThe platform serves oncologists and cancer centers by providing AI-augmented pathology reads, treatment outcome predictions, and clinical trial matching. Pathos's AI can analyze whole-slide pathology images in combination with molecular and clinical data to generate insights that inform diagnosis and treatment decisions. The company has also built partnerships with pharmaceutical companies — including Novo Nordisk and Prelude Therapeutics — to use its platform for drug development and clinical trial design, adding a biopharma revenue stream alongside its clinical business.\n\nPathos raised $365M in a Series D round at a $1.6B valuation, bringing total funding to $467M. The Series D was one of the largest oncology AI fundraises in history and included backing from top-tier life sciences investors. The Novo Nordisk and Prelude partnerships validate the platform's scientific depth and its utility across both clinical care and drug development. As of 2025–2026, Pathos is advancing toward direct clinical deployment and regulatory submissions, positioning itself as a core infrastructure layer for the future of AI-guided cancer treatment.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#289
Category Rank
#1
82
AI Consensus
80
stable
Trend
up
48
ChatGPT
94
54
Perplexity
89
50
Gemini
94
47
Claude
92
47
Grok
98

Key Details

Category
AI Oncology
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Pathos AI
AI Oncology

Integrations

Only Pfizer
Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.